DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and ...
Results Presented at the AAAAI Meeting Showed CoFAR6 Met Primary Endpoint, With a Strong Response Observed in Children Early Mechanistic Results are In-Line with DBV's Preclinical Findings MONTROUGE, France, March 4, 2016 (GLOBE NEWSWIRE) -- DBV …